Liu Kaixiang, Yu Min, He Yangyang, Wang Ting, Li Guisen, Wang Li, Zhong Xiang
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Front Pharmacol. 2025 Jul 22;16:1610573. doi: 10.3389/fphar.2025.1610573. eCollection 2025.
Renal fibrosis is a common characteristic of chronic kidney disease (CKD). Studies have confirmed the role of ferroptosis in the pathogenesis of various kidney diseases, making it a new research hotspot in the field of renal fibrosis. Monomers of Chinese herbal medicines (CHMs) can improve renal fibrosis by multi-target inhibition of ferroptosis. This review aimed to explore the roles and mechanisms of CHMs in renal fibrosis.
Using the keywords "ferroptosis", "chronic kidney disease", "renal fibrosis", "Chinese herbal medicine", "natural products", "bioactive components", and "herb", we conducted an extensive literature search of several databases, including PubMed, Web of Science, CNKI, and Wanfang database, to identify studies reporting the role of CHM monomers in inhibiting ferroptosis and improving renal fibrosis. The names of the plants covered in the review have been checked through MPNS (http://mpns.kew.org). All monomers of CHMs were identified in the Pharmacopoeia of the People's Republic of China.
In total, 21 monomers of CHMs were identified in this study, most of which were flavonoids, followed by terpenoids and coumarins. This review showed that monomers of CHMs inhibited ferroptosis and improved renal fibrosis through multi-target mechanisms. They maintained iron homeostasis by acting on NCOA4 and Nrf2 to reduce ferritinophagy. They also inhibited lipid peroxidation and regulated the antioxidant system by modulating ACSL4, NOX4, Nrf2, FSP1, and GPX4 and inhibiting Smad3 to improve renal fibrosis.
Monomers of CHMs effectively inhibited ferroptosis and prevented renal fibrosis in various animal models and cell models of CKD. However, further in-depth studies with better designs are needed to identify the exact targets of monomers of CHMs and improve the treatment of renal fibrosis and CKD.
肾纤维化是慢性肾脏病(CKD)的常见特征。研究已证实铁死亡在各种肾脏疾病发病机制中的作用,使其成为肾纤维化领域的一个新研究热点。中草药单体可通过多靶点抑制铁死亡来改善肾纤维化。本综述旨在探讨中草药在肾纤维化中的作用及机制。
使用关键词“铁死亡”“慢性肾脏病”“肾纤维化”“中草药”“天然产物”“生物活性成分”和“草药”,对多个数据库进行广泛文献检索,包括PubMed、Web of Science、中国知网和万方数据库,以识别报道中草药单体在抑制铁死亡和改善肾纤维化方面作用的研究。综述中涉及的植物名称已通过MPNS(http://mpns.kew.org)进行核对。所有中草药单体均在中国药典中得到确认。
本研究共鉴定出21种中草药单体,其中大部分为黄酮类,其次是萜类和香豆素类。本综述表明,中草药单体通过多靶点机制抑制铁死亡并改善肾纤维化。它们通过作用于NCOA4和Nrf2来维持铁稳态,以减少铁自噬。它们还通过调节ACSL4、NOX4、Nrf2、FSP1和GPX4并抑制Smad3来抑制脂质过氧化并调节抗氧化系统,从而改善肾纤维化。
中草药单体在各种CKD动物模型和细胞模型中有效抑制铁死亡并预防肾纤维化。然而,需要进一步开展设计更优的深入研究,以确定中草药单体的确切靶点,并改善肾纤维化和CKD的治疗。